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Lung cancer is the leading cause of cancer dearth. Cigarette smoking is the strongest risk factor for developing lung cancer,
which is conceivably initiated by proliferation. Here, we show that low concentration of aqueous extract of cigarette smoke
(AECS) causes excessive proliferation of human lung epithelial cells (A549) without any apoptotic cell death. The causative
factor responsible for AECS-induced proliferation has been identified as p-benzoquinone (p-BQ). Coimmunoprecipitation and
immunoblot experiments indicate that p-BQ binds with epidermal growth factor receptor (EGFR). However, in contrast to EGF,
it causes aberrant phosphorylation of EGFR that lacks c-Cbl-mediated ubiquitination and degradation resulting in persistent
activation of EGFR. This is followed by activation of Hras + Kras and the downstream survival and proliferative signaling molecules
Akt and ERK1/2, as well as the nuclear transcription factors c-Myc and c-Fos. Vitamin C and/or antibody to p-BQ prevents
AECS/p-BQ-induced proliferation of lung cells apparently by inactivating p-BQ and thereby preventing activation of EGFR and
the downstream signaling molecules. The results suggest that vitamin C and/or antibody to p-BQ may provide a novel intervention
for preventing initiation of lung cancer in smokers.
1. Introduction
Lung cancer is the leading cause of cancer death in the United
States and throughout the world [1]. Cigarette smoking is the
strongest risk factor for developing lung cancer. Smoking and
exposure to environmental tobacco smoke account for 90%
of lung cancer cases, and smokers have a 20-fold increased
risk of death from lung cancer compared to nonsmokers [2].
However, the carcinogenic mechanisms of tobacco smoking
are not well understood [3]. The most significant property of
cancer cells is that they undergo excessive proliferation. Lung
cancer arises after a series of progressive pathologic changes
(preneoplastic lesions) that are initiated by proliferation
(hyperplasia) [4]. In almost all instances, unregulated cell
proliferation together with suppressed apoptosis constitutes
the minimal common platform upon which all neoplastic
progression occurs [5]. It has been proposed that increased
proliferative activity is causally linked to carcinogenesis and
tumor progression [6]. Experimental and theoretical support
for the hypothesis that increased proliferation itself is a con-
tributory factor to carcinogenesis stems mainly from studies
with chemical carcinogens in rodent tumor models and
mathematical modeling of tumor progression [7]. Clinical
observations also suggest a possible contributory role of
increased cell proliferation to genesis and/or progression of
human cancers [7]. Since cigarette smoke (CS) causes lung
cancer, it is expected that CS should promote cell division.
In fact, preliminary observations indicate that hyperprolif-
eration of cells occurs in response to smoke exposure [8–10].
However, the molecular mechanisms of CS-induced cell
proliferation are yet to be known. This is particularly because
cigarette smoke (CS) is a highly complex mixture containing
about 4000 compounds, including carcinogens, free radicals,
and long-lived radicals such as semiquinones [11, 12]. It is
a conjecture whether one particular compound or a number
of compounds in CS are responsible for proliferation of
cells. We have isolated a major semiquinone from CS and
characterized it as p-benzosemiquinone (p-BSQ) [13, 14]. p-
BSQ is present in substantial amounts (100–200μg/cigarette)
in smoke from all commercial cigarettes examined as well as
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Kentucky research cigarettes [15]. p-BSQ causes cytotoxicity
and tissue damage through conversion to p-benzoquinone
(p-BQ), which occurs by disproportionation and oxidation
by transition metal-containing proteins [14, 16]. Here, we
show that CS-induced proliferation of lung cells is com-
pletely prevented by antibody to p-BQ and that p-BQ in
amounts derived from CS mimics CS-induced lung cell
pro-liferation. Overexpression and/or hyperactivity of the
epidermal growth factor receptor (EGFR), accompanied
by several downstream cytoplasmic signal transducers, in-
cluding Ras-MAPK cascade as well as the cell survivor factor
Akt (protein kinase B) has been shown to play a causal role
in the proliferation and progression of lung tumors [4].
Lemjabbar et al. observed that CS-induced cell proliferation
was accompanied by phosphorylation (activation) of the
epidermal growth factor receptor (EGFR) [9]. Abdelmohsen
et al. showed that p-BQ induced activation of extracellular
signal-regulated kinase ERK1/2 via the activation of EGFR
[17]. Here, we demonstrate that p-BQ, apparently derived
from p-BSQ of aqueous extract of CS (AECS), is responsible
for AECS-induced cell proliferation via activation of EGFR,
Ras, ERK1/2, and Akt as well as the transcription factors
c-Myc and c-Fos. p-BQ is strongly inactivated by vitamin
C, and earlier we had reported that CS-induced cytotoxicity
and lung damage is prevented by vitamin C [18–22]. Here,
we show that both antibody to p-BQ and vitamin C prevent
AECS/p-BQ-induced proliferation of human lung cells
apparently by inactivating p-BQ.
2. Materials and Methods
2.1. Chemicals and Reagents. p-Benzoquinone (p-BQ) was
procured from Merck and freshly crystallized before use.
Benzo[a]pyrene (BP) was obtained from Fluka. 4-(Meth-
ylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-
nitrosonornicotine (NNN) were obtained from Toronto
Research Chemicals Inc. Tyrphostin AG1478 was purchased
from Sigma-Aldrich, USA. The “In Situ Cell Proliferation
Kit, FLUOS” was obtained from Roche Applied Science,
Germany. The Annexin V-FITC kit was purchased from BD
Biosciences. The kit for protein estimation was purchased
from Bio-Rad, USA and the Protein A-Sepharose CL-42
beads from GE Healthcare, USA. The chemiluminescence kit
for immunoblot analysis was procured from Cell Signaling
Technology, USA. All other chemicals were of analytical
grade. The antibody to p-BQ, raised in rabbit after immu-
nization with p-BQ-bovine serum conjugate, was supplied
by Abexome Biosciences, Bangalore, India.
2.2. Cigarettes. All the experiments were performed using
cellulose-acetate filter-tipped Kentucky reference cigarettes
(3R4F) obtained from the University of Kentucky, College
of Agriculture Reference Cigarette Program, Lexington,
Kentucky, USA.
2.3. Preparation of Aqueous Extract of Cigarette Smoke (AECS)
Solution. The method of preparation of AECS was so devised
as to simulate the manner in which the respiratory tract
lining fluid is exposed to CS during the process of smoking by
humans [18]. Smoke from one cigarette was extracted with
1 mL of 50 mM potassium phosphate buffer, pH 7.4, filtered
through 0.22 μm Millipore filter and the pH adjusted to 7.4.
The aqueous extract of CS (AECS) solution thus obtained
was used immediately.
2.4. Measurement of p-Benzoquinone (p-BQ). p-BQ was
measured by HPLC as described before [14]. The column
used was a LichroCART 350-4, RP-18 (5 μm) (Merck). p-
BQ was detected at 245 nm at the retention time of 4.75 min
using a mobile solvent of methanol: water (90 : 10 v/v) at a
flow rate of 0.5 mL/min. The limit of detection was 500 pg.
2.5. Cell Culture. A549 human lung carcinoma cells were
maintained in Hams F12 medium (GIBCO-BRL, USA)
containing 10% fetal calf serum (GIBCO-BRL, USA),
100 units/mL penicillin, 100 μg/mL streptomycin, and 4 mM
glutamine/mL. L132 (normal human lung epithelial cells),
Vero (African green monkey kidney cell line), and HepG2
(human liver cell line) cells were maintained in Dul-
becco’s Modified Eagle Medium (GIBCO-BRL, USA), con-
taining 10% fetal calf serum (GIBCO-BRL, USA), 100 units/
mL penicillin, 100 μg/mL streptomycin, and 4 mM glu-
tamine/mL. All the cells were obtained from National Centre
for Cell Sciences (NCCS Pune, India). The cells were grown
at 37◦C in a humified incubator maintained in an atmos-
phere of 95% air and 5% CO2.
2.6. Cytotoxicity Assay. The cytotoxicity of AECS, p-BQ,
NNN, NNK, and BP was evaluated by the 3-(4,5-dim-
ethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay, as described earlier [15]. Briefly, after treatment with
different compounds, the culture medium was replaced
with serum-free medium containing 0.5 mg/mL MTT, and
cultures were incubated for an additional 3 hr. The blue
MTT formazan thus formed was dissolved in DMSO, and
the absorbance values were measured at 560 nm in a UV-VIS
spectrophotometer (Shimadzu UV-2540).
2.7. Cell Cycle Analysis by Flow Cytometry. To estimate the
percentage of cells at different stages of cell cycle, cultured
cells (3×106), after specified treatment with AECS/p-BQ for
1 hr, were washed with PBS solution and incubated in fresh
culture medium for 12 hr. Cell cycle analysis was performed
by propidium iodide (PI) according to manufacturer’s pro-
tocol and analyzed using the FACS Calibur-Cell Quest soft-
ware. A total of 10,000 events were acquired, and a histogram
plot of FL2-H was recorded.
2.8. Assessment of Apoptosis by Flow Cytometry. To estimate
the percentage of cells undergoing apoptosis, cultured cells
(3 × 106), after specified treatment with AECS for 1 hr,
were washed with PBS solution (Hyclone, Thermo Scientific)
and incubated in fresh culture medium for 12 hr. Apoptosis
was assessed by Annexin V and propidium iodide (PI)
(Becton Dickinson) according to manufacturer’s protocol
and analyzed using the FACS Calibur-Cell Quest software
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(Becton Dickinson) as described earlier [15]. A total of
10,000 events were acquired, and dual parameter dot plot
of FL2-H (x-axis; PI-fluorescence, linear scale) versus FL1-
H (y-axis; Annexin V-FITC-fluorescence, linear scale) was
recorded.
2.9. Lysate Preparation, Immunoprecipitation, and Immun-
oblotting. Lysate preparation and protein immunoprecip-
itation were performed as described by Bao et al. [23].
After treatment, cells were extracted in solubilization buffer
containing 50 mM Tris, pH 7.5; 150 mM NaCl; 10% glycerol;
1% Nonidet P-40; 1 mM EDTA; Protease Inhibitor Cocktail
(Sigma); Phosphatase Inhibitor Cocktail (Sigma). Lysates
were cleared by centrifugation at 20,000 g for 10 min at 4◦C,
and the total protein concentration was estimated. Protein
(400 μg) in the supernatant was immunoprecipitated by
overnight incubation with 4 μg anti-EGFR antibody (Cell
Signaling Technology, USA) at 4◦C, followed by Protein
A-Sepharose CL-42 (GE Healthcare) precipitation for 3 hr at
4◦C. Immunoprecipitates were washed 3 times with HNTG
buffer containing 20 mM HEPES, pH 7.5; 150 mM NaCl;
0.1% Triton X-100; 10% glycerol, resolved by SDS-PAGE,
and transferred to PVDF membrane. Membranes were
blocked for 1 hr in Tris-buffered saline, pH 7.5; containing
0.5% Tween 20 and 5% nonfat milk (Bio-Rad), incubated
overnight at 4◦C with primary antibody (1 : 1000), followed
by 1 hr incubation at room temperature with 1 : 3000
dilution of HRP-conjugated secondary antibody (Cell
Signaling Technology, USA). Immunoreactive protein
bands were detected by chemiluminescence. Blotting anti-
bodies used were anti-EGFR, anti-p-BQ, anti-p53, anti-
phospho-p53, anti-Caspase 3, anticleaved Caspase 3, anti-
Akt, anti-phospho-Akt, anti-phosphotyrosine-845, anti-
phosphotyrosine-1045, anti-phosphotyrosine-1068, anti-
phosphotyrosine-1086, anti-ERK1/2, anti-phospho-ERK1/2,
anti-c-Fos, anti-c-Cbl, antiubiquitin(UbC3) (Cell Signaling
Technology, USA), antiphosphotyrosine PY20, anti-phos-
photyrosine-1173, anti-β actin (Santa Cruz Biotechnology,
USA), anti-HRAS + KRAS, anti-c-Myc, and anti-phospho-
c-Myc (phospho T58+S62) (abcam, UK).
2.10. Detection of Reactive Oxygen Species (ROS) Production.
Prior to treatment, cells were incubated for 30 min with
10μM 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA)
(Sigma-Aldrich). Fluorescent images were captured using
confocal laser scanning microscope (LSM 510 META, Carl
Zeiss).
2.11. Cell Proliferation Assay. Cell proliferation was assessed
using the “In Situ Cell Proliferation Kit, FLUOS” (Roche
Applied Science, Germany), according to the manufacturer’s
protocol. Briefly, after treatment the cells were incubated
in serum-free medium containing 10 μM BrdU Labeling
Solution for 5 hr at 37◦C. Cells were washed with PBS
and fixed for 30 min at 4◦C in fixative solution, containing
50 mM glycine (pH 2.0) in 70% (V/V) ethanol. Cells were
then permeabilized for 20 min at room temperature with
denaturation solution, containing 4 M HCl, followed by
subsequent PBS washes until the pH reached above 6.5.
To block nonspecific binding, cells were then incubated for
10 min at room temperature in incubation buffer, containing
PBS, 0.5% BSA, and 0.1% Tween 20. Cells were then
incubated with anti-BrdU-FLUOS antibody for 45 min at
37◦C in a humid chamber. After incubation, cells were
washed with PBS and analyzed by flow cytometry using the
FACS Calibur-Cell Quest software (Becton Dickinson). A
total of 10,000 events were acquired, and a histogram plot
of FL1-H was recorded.
2.12. Statistical Analysis. All values are expressed as mean
± SD. Statistical significance was carried out using one-way
ANOVA. The P values were calculated using appropriate F-
tests. Difference with P values <.05 was considered signifi-
cant.
3. Results and Discussion
3.1. Proliferation of Human Lung Epithelial Cells (A549) by
AECS/p-BQ. Using MTT assay here we show that whereas
low concentration of aqueous extract of cigarette smoke
(AECS) induces proliferation of human lung epithelial
cells in culture (A549), high concentrations lead to cell
death (Figure 1(a)). The optimum AECS concentration that
causes maximum cell proliferation is about 2 μL/mL. The
proliferation is not restricted to A549 cells; it also occurs in
other cell lines, such as L132 (normal human lung epithelial
cells), Vero (African green monkey kidney cell line), and
HepG2 (human liver cell line) (Figure 1(b)). The AECS-
induced proliferation is mimicked by the amount of p-BQ
(200 ng/mL) produced in the culture medium from 2 μL/mL
of AECS (Figure 1(c)). The amount of p-BQ formed from
AECS in the incubation mixture was determined by HPLC.
Like that observed with AECS, high concentrations of p-
BQ cause cell death (Figure 1(c)). A single treatment with
AECS (2 μL/mL) or p-BQ (200 ng/mL) results in continued
proliferation for 24–72 hr (Figure 1(d)).The proliferation by
either AECS or p-BQ is completely prevented by antibody
to p-BQ (Figure 1(e)). The inhibitory role of anti-p-BQ
antibody on the proliferation of A549 cells has also been
confirmed by the incorporation of BrdU using flow cytom-
etry analysis (Figures 1(f) and 1(g)). The results indicate
that p-BQ derived from AECS is responsible for AECS-
induced proliferation of the lung cells. The AECS used
was prepared from Kentucky research cigarettes (3R4F).
Similar results were obtained by AECS prepared from a
commercial cigarette (Wills Navy Cut, India; results not
shown), indicating that the observations were not specific to
Kentucky research cigarettes.
p-BQ is not present in CS, but is formed from p-ben-
zosemiquinone (p-BSQ), a long-lived semiquinone present
in substantial amounts (100–200μg/cigarette) in smoke
from Kentucky research cigarettes as well as a number
of commercial cigarettes examined [15]. p-BSQ is present
exclusively in the tar phase of CS and is extracted in the AECS
[12, 14]. p-BSQ is converted to p-BQ by disproportionation
(2 p-BSQ→p-BQ + HQ) [16], as well as oxidation by
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Figure 1: Continued.
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Figure 1: AECS/p-BQ-induced proliferation of human lung epithelial cells (A549) and its prevention by anti-p-BQ antibody. Except in
(d), all the treatments were made in 24 hr. Effect of concentration gradient of AECS on proliferation and death of A549 cells in culture, as
determined by MTT cytotoxicity assay (a). AECS (2μL/mL) or p-BQ (200 ng/mL)-induced proliferation in other cell lines, namely. L132,
Vero, and HepG2 (b). Effect of concentration gradient of p-BQ on proliferation and death of A549 cells in culture, as determined by MTT
cytotoxicity assay (c). Treatment with AECS (2 μL/mL) or p-BQ (200 ng/mL) results in continued proliferation for 24–72 hr (d). AECS/p-
BQ-induced proliferation is prevented by anti-p-BQ antibody, as evidenced by MTT assay (e). The inhibitory role of anti-p-BQ antibody
on the proliferation of A549 cells as determined by the incorporation of BrdU using flow cytometry assay (f, g). All data are depicted as the
mean ± SD for three independent experiments (∗ indicates significant difference, P < .05 in comparison to nontreated control (a, b, c, d);
and in comparison to AECS and p-BQ, resp. (e, g)).
transition metal (Fe3+, Cu2+) containing proteins (p-BSQ→
p-BQ) [14]. The method of preparation of AECS was so
devised as to simulate the manner in which the respiratory
tract lining fluid is exposed to CS during the process of
smoking by humans [18]. Cigarette tar is continually being
deposited in the lungs of smokers, and these lungs are
continually bathed in an aqueous solution that can solubilize
and transport the water soluble components of the tar [12].
p-BSQ present in cigarette tar can be extracted into aqueous
solutions and thus would be in solutions bathing a smoker’s
lung [12]. In CS solution produced in the lungs, p-BSQ
would be converted to p-BQ and induce proliferation of
cells. This is supported by the observation that CS causes cell
proliferation in the lungs of rat in vivo [8].
3.2. Cell Cycle Analysis of the Proliferating Cells. The rate of
cell proliferation within any population of cells depends on
three parameters: (a) the rate of cell division, (b) the fraction
of cells within the population undergoing cell division,
and (c) the rate of cell loss from the population due to
terminal differentiation or cell death. Failure to regulate these
functions properly results in an altered phenotype and cancer
[19]. Here, we have performed the cell cycle analyses using
propidium-iodide (PI) staining followed by flow cytometry.
Figure 2(a) shows the histogram plot of A549 cells either
nontreated (NT) or exposed to 2 μL/mL AECS or 200 ng/mL
p-BQ for 24 hr. The mean fluorescence of 2 μL/mL AECS or
200 ng/mL p-BQ-treated cells was significantly higher (P <
.05) than that of the nontreated cells. However, pretreatment
with 40 μg/mL vitamin C for 15 min completely reduces
the mean fluorescence (Figure 2(b)). In addition to the
relative cellular DNA content, the cell distribution during
the various phases of the cell cycle was also determined
(Figure 2(c)). Three distinct phases were recognized in the
AECS/p-BQ-induced proliferating cell population: the G0-
G1 (Region “M1” in Figure 2(a)), S or the DNA synthesis
phase (Region “M2” in Figure 2(a)), and the G2-M phase
(Region “M3” in Figure 2(a)). Also, the percentages of
cells occupying the different phases of the cell cycle were
calculated (Figure 2(c)). Figure 2(c) shows that compared
to the nontreated cells (30.2%), cells treated with 2 μL/mL
AECS or 200 ng/mL p-BQ have higher number of cells
(40.55% or 47.45% of the total cell population, resp.) in the
S-phase, indicating markedly higher rate of DNA synthesis.
However, pretreatment with 40 μg/mL vitamin C for 15 min
prior to treatment with 2 μL/mL AECS or 200 ng/mL p-BQ
reduces the percentage of cells in S-phase to 30.15% and
31.35%, respectively (Figures 2(a), 2(b), and 2(c)), indicating
prevention of higher rate of DNA synthesis.
3.3. Vitamin C Prevents AECS/p-BQ-Induced Proliferation of
Cells. We have previously shown that CS produces toxicity
and tissue damage only in marginal vitamin C-deficient
guinea pigs, but not in vitamin C-sufficient ones [14, 18, 20].
We had also shown that a moderately large dose of vitamin
C prevents CS-induced toxicity, apparently by reducing and
inactivating p-BQ (14). This is because vitamin C (E◦ =
+0.08 V) strongly reduces p-BQ (E◦ = +0.71 V) to less toxic
hydroquinone and thereby inactivates p-BQ. Here, we show
that p-BQ derived from AECS causes proliferation of lung
cells in serum-free medium (Figure 1), which is essentially
free of vitamin C. MTT assay also indicates that 40 μg/mL
vitamin C prevents AECS/p-BQ-induced proliferation of
A549 cells (Figure 3(a)). At this concentration, vitamin C
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Figure 2: Cell cycle analysis of proliferating A549 cells. Histogram plot (Event count versus FL2-H) of AECS/p-BQ-induced proliferation of
A549 cells and its prevention by vitamin C as determined by propidium iodide (PI) staining followed by flow cytometry (a). Bar diagram
showing mean fluorescence of PI (FL2-H) in cells either nontreated (NT) or exposed to 2 μL/mL AECS or 200 ng/mL p-BQ for 24 hr and
its prevention by vitamin C (40μg/mL) (b). Bar diagram showing the relative cell distribution during various phases of the cell cycle after
exposure to 2 μL/mL AECS or 200 ng/mL p-BQ (c). Data are means ± SD for three independent experiments (∗ in (b) and (c) indicates
significant difference, P < .05 in comparison to AECS and p-BQ treatment).
does not have any effect on the growth of nontreated (NT)
cells in the absence of AECS/p-BQ (data not shown). The
inhibitory role of vitamin C has been confirmed by BrdU
incorporation, as evidenced by flow cytometry assay (Figures
3(b) and 3(c)).
The role of vitamin C in the prevention and treatment of
cancer has a long and controversial history. Although there
has been a paucity of human studies using vitamin C to
treat already existing cancer, there is considerable epidemi-
ological evidence pointing to the benefits of vitamin C in
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Figure 3: Vitamin C prevents AECS/p-BQ-induced proliferation of cells. AECS/p-BQ-induced proliferation is prevented by vitamin C
(40 μg/mL), as evidenced by MTT assay (a), as well as BrdU-incorporation assay (b and c). Serum-starved A549 cells (2000 cells/well) grown
on 96-well tissue culture plates were either nontreated (NT) or exposed to 2 μL/mL AECS or 200 ng/mL p-BQ for 24 hr with or without
vitamin C (40 μg/mL) pretreatment in serum-free medium for 15 min (a, b, and c). Data represent means ± SD for three independent
experiments (∗ indicates significant difference, P < .05 in comparison to AECS (2 μL/mL) and p-BQ (200 ng/mL), resp.).
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Figure 4: Effect of low or high concentration of AECS/p-BQ on reactive oxygen species (ROS) production in cultured A549 cells and its
prevention by vit C. Serum-starved A549 cells grown on coverslips were either nontreated (NT) or exposed to 2 μL/mL AECS, 50 μL/mL
AECS, 200 ng/mL p-BQ or 2.5 μg/mL p-BQ for 1 hr with or without vitamin C (40 μg/mL) pretreatment in serum-free medium for 15 min.
After treatment, cells were incubated in fresh media containing H2DCFDA for 30 min and PBS washed twice, and fluorescent images were
captured.
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Figure 5: Status of p53, phospho-p53, caspase 3, cleaved-caspase 3 and apoptosis in cultured A549 cells exposed to low or high concentration
of AECS/p-BQ. The figure represents immunoblots of phosphorylated p53 and p53 (a) and caspase 3 and cleaved caspase 3 (b). Cell lysate of
A549 cells were either nontreated (NT) or exposed to AECS (2 μL or 50 μL/mL) or p-BQ (200 ng or 2.5 μg/mL) for 1 hr followed by incubation
in serum containing media for 12 hr. Vitamin C (40 μg/mL) pretreatment of cells in serum-free media for 15 min prevented AECS/p-BQ-
induced activation of p53 or cleavage of caspase 3 (a, b). β-actin was used as the loading control. Effect of low or high concentrations of
AECS/p-BQ on apoptosis in cultured A549 cells and its prevention by vitamin C as evidenced by flow cytometry (c). A549 cells were grown
on 60 mm culture plates and were gradually serum starved for 3 days to synchronize the cells. Then the cells were either nontreated (NT)
or exposed to 2 μL/mL or 50 μL/mL AECS for 1 hr, 200 ng/mL or 2.5 μg/mL p-BQ for 1 hr, with or without 40 μg/mL vit C pretreatment in
serum-free medium for 15 min. After treatment, cells were incubated in fresh media containing serum for 12 hr, followed by Annexin V-PI
assay. Bar graphs show the percentage of normal and apoptotic cells after respective treatments, as evidenced by flow cytometry (d). The
numbers within the bars represent percentage of normal and apoptotic cells.
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the prevention of a number of types of cancer, including
lung cancer [24, 25]. Almost 90% of lung cancer is due
to cigarette smoking [2]. We had shown that CS consumes
vitamin C [18]. This would corroborate the observations
by other researchers that lung cancer patients usually suffer
from hypovitaminosis C [25]. Several clinical trials of cancer
and vitamin C demonstrated remarkable tolerance and safety
for high dose of vitamin C in patients [26].
It has been shown above that in contrast to low concen-
tration, high concentration of AECS/p-BQ (50 μL/mL AECS
or 2.5 μg/mL p-BQ) results in cell death (Figure 1(a)). The
death is apparently caused by oxidative stress and apoptosis.
The oxidative stress has been evidenced by the formation
of ROS (Figure 4) and apoptosis by the phosphorylation
of p53 (Figure 5(a)) and activation (cleavage) of caspase 3
(Figure 5(b)). Apoptosis was supported by Annexin V/PI
assay using flow cytometry (Figures 5(c) and 5(d)). Vitamin
C prevents cell death apparently by preventing oxidative
stress (Figure 4) and apoptosis (Figure 5). No such oxidative
stress or apoptosis was observed with low concentration of
AECS (2 μL) or p-BQ (200 ng) that induced proliferation of
cells (Figures 4 and 5).
3.4. Effects of NNK, NNN, and BP on Cell Proliferation.
Cigarette smoke is a complex mixture of 4000 com-
pounds containing carcinogens, including polycyclic aro-
matic hydrocarbons (PAHs) and nitrosamines. Among PAH,
the most extensively studied is benzo[a]pyrene (BP) and
among nitrosamines, 4-(Methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) and N-nitrosonornicotine (NNN) [11].
Compared to p-BSQ (100–200 μg/cigarette) [15], the con-
centrations of these carcinogens in smoke from one cigarette
are very low: BP, 20–40 ng; NNK, 80–770 ng; NNN, 1.1–
2.9 μg [11, 27]. These carcinogens produce tumor in rodents
only at very high doses [11]. Here, we show that under
the experimental conditions, NNN, NNK, and BP do not
cause any proliferation of A549 cells (Figures 6(a), 6(b),
and 6(c)). At high concentrations, the carcinogens are rather
inhibitory to the growth of the cells. Moreover, none of
them has any synergistic effect on the proliferation of A549
cells by AECS or p-BQ (data not shown). Although BP,
NNK, and NNN do not induce proliferation of cells, but
they may exert their carcinogenic effects on p-BQ-induced
cell proliferation. Proliferation (cell division) triggers mitotic
recombination, gene conversion, and nondisjunction. The
time interval for DNA repair during mitosis is short. The
DNA is also transiently not base paired or bound to histones,
therefore making it more sensitive to chance of adduct
formation with DNA and mutation by BP, NNK, and NNN,
ultimately leading to carcinogenesis.
3.5. AECS/p-BQ-Induced Cell Proliferation Occurs via the
Activation of EGFR That Is Prevented by Vitamin C. Epi-
dermal growth factor receptor (EGFR) is composed of an
extracellular ligand binding domain, a transmembrane do-
main, and an intracellular tyrosine kinase (receptor tyrosine
kinase, RTK)) domain. Activation of the receptor leads
to an intracellular signaling cascade that controls cel-
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Figure 6: Effects of concentration gradient of NNN (a), NNK
(b), and BP (c) on the growth of cultured A549 cells after 24, 48,
and 72 hr as evidenced by MTT assay. Serum-starved A549 cells
(2000 cells/well) grown on 96-well tissue culture plates were either
nontreated (0) or exposed to 0.025, 0.05, 0.1, 0.5, or 1 μg/mL NNN
(a), NNK (b), and BP (c) for 24, 48, and 72 hr. After treatment, MTT
cytotoxicity assay was performed. All data are depicted as the means
± SD for four independent experiments.
lular proliferation and differentiation. Ligands for these
receptors, most importantly epidermal growth factor (EGF)
and transforming growth factor-α (TGF-α), bind to the
extracellular domain resulting in receptor dimerization and
autophosphorylation of the intracellular receptor tyrosine
kinase (RTK) domain, leading to downstream signaling,
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Figure 7: p-BQ mimics AECS in activating EGFR in a time-dependent manner. Serum-starved A549 cells were nontreated (NT) or exposed
to 100 ng/mL EGF for 5 min, 2 μL/mL AECS or 200 ng/mL p-BQ for 15 min, 30 min, or 1 hr, respectively (a). Vitamin C (40 μg/mL)
pretreatment of A549 cells for 15 min in serum-free media completely prevented AECS/p-BQ-induced EGFR activation (b). 500 nM
Tyrphostin AG1478 (EGFR inhibitor) pretreatment of A549 cells for 15 min in serum-free media completely prevented activation of EGFR
by 100 ng/mL EGF, 2 μL/mL AECS, or 200 ng/mL p-BQ (c). Anti-p-BQ antibody prevented AECS/p-BQ-induced EGFR activation (d). Cells
were lysed, and the EGFR was immunoprecipitated (IP) from the cell lysates using anti-EGFR antibody. Immunoprecipitated proteins were
separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted (IB) with either antiphosphotyrosine (PY20) antibody (a, b,
c) or with anti-p-BQ antibody (d).
including the activation of ras, raf, mitogen-activated pro-
tein kinase (MAPK), phosphatidyl-3 kinase (PI3K/Akt),
and ERK1/2. These molecules are linked to cell growth,
proliferation, motility, and survival [28]. Previous studies
revealed that EGFR is activated (phosphorylated) in a dose-
and time-dependent manner when exposed to CS solution
[29]. However, CS is a highly complex mixture, and the
component(s) of cigarette smoke solution responsible for
cell proliferation has not been known. Using human lung
epithelial cells (A549), here we show that p-BQ (200 ng/mL)
derived from AECS (2 μL/mL) is responsible for AECS-
induced phosphorylation of EGFR. (Figure 7(a)). The acti-
vation (phosphorylation) of EGFR by EGF is mediated by
noncovalent interactions, and the phosphorylation appears
to be high after 5 min (Figure 7(a)), which decays after
15 min as shown by others [29]. On the other hand, p-BQ
derived from AECS covalently binds with the extracellular
domain of EGFR tentatively by Michael addition with Lys
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Figure 8: AECS/p-BQ exposure results in aberrant phosphoryla-
tion of the EGFR. Serum-starved A549 cells were either nontreated
(NT) or exposed to 100 ng/mL EGF for 5 min, 2 μL/mL AECS or
200 ng/mL p-BQ for 1 hr. Cells were lysed, and the EGFR was
immunoprecipitated (IP) from the cell lysates using anti-EGFR
antibody. Immunoprecipitated proteins were separated by SDS-
PAGE, transferred to PVDF membrane, and immunoblotted (IB)
with indicated EGFR phosphotyrosine-specific antibodies or anti-
EGFR antibodies.
residue [30] and activates the EGFR constitutively. In this
case, the phosphorylation by p-BQ starts at about 15 min
after treatment and persists for 1 hr, indicating prolonged
activation of EGFR. It is reported that constant activation of
EGFR results in uncontrolled cell division—a predisposition
for cancer, including lung cancer [31, 32]. This would
indicate that p-BQ may be a risk factor for the initiation
of CS-induced lung cancer. Given that more than 80% of
nonsmall cell lung carcinomas (NSCLCs) express EGFR [2],
EGFR has become an important therapeutic target for the
treatment of these tumors. This led to the development
of EGFR inhibitors for anticancer treatment [33, 34]. The
most common approaches use either monoclonal antibodies
that competitively bind to the extracellular domain or small
molecules targeting the intracellular RTK domain. Vitamin
C inactivates p-BQ, and we have shown that vitamin C
pretreatment of cells prior to AECS/p-BQ exposure com-
pletely prevents EGFR activation (Figure 7(b)). This would
suggest that intake of vitamin C would prevent lung cell
proliferation and initiation of carcinogenesis in smokers.
Vitamin C does not prevent EGF-induced phosphorylation
of EGFR (data not shown). In order to confirm that AECS/p-
BQ induced activation of EGFR, we performed the aforesaid
experiment in the presence of 500 nM AG1478 (Tyrphostin,
EGFR kinase inhibitor). The results (Figure 7(c)) indicate
that 500nM AG1478 completely prevents activation of EGFR
by 100 ng/mL EGF, 2 μL/mL AECS, or 200 ng/mL p-BQ.
In a separate coimmunoprecipitation experiment, we show
that anti-p-BQ antibody prevents AECS-induced EGFR
activation (Figure 7(d)). This would indicate that antibody
to p-BQ might also be a candidate for the prevention of the
initiation of cell proliferation and lung cancer in smokers.
3.6. AECS/p-BQ Exposure Results in Aberrant Phosphorylation
of the EGFR. EGFR dimerization stimulates its intrinsic
intracellular protein-tyrosine kinase activity. As a result,
autophosphorylation of several tyrosine (Y) residues in the
C-terminal domain of EGFR occurs. These include Y845,
Y1045, Y1068, Y1148, and Y1173 [35]. This autophosphoryl-
ation elicits downstream activation and signaling by several
other downstream signaling proteins that initiate several
signal transduction cascades, principally the MAPK, Akt, and
JNK pathways, leading to DNA synthesis and cell prolif-
eration. Such proteins modulate phenotypes including cell
proliferation [36]. Earlier studies indicate that CS exposure
resulted in the aberrant phosphorylation of the EGFR [29].
Because p-BQ mimics AECS in activating the EGFR, we
wanted to see whether p-BQ also causes aberrant phospho-
rylation of EGFR. Immunoblot analyses of EGFR from A549
cells exposed to 100 ng/mL EGF for 5 min, 2 μL/mL AECS
for 1 hr, or 200 ng/mL p-BQ for 1 hr show that AECS/p-BQ
exposure results in similar aberrant phosphorylation pattern
that is distinctly different from EGF exposure (Figure 8).
After incubation with AECS/p-BQ, Tyr-845 is hyperphos-
phorylated, but Tyr-1045 is not phosphorylated. With EGF
exposure, Tyr-1045 is strongly phosphorylated, whereas Tyr-
845 is phosphorylated to a much lesser extent. The pattern of
phosphorylation of Tyr-1068, 1086, and 1173 appears to be
almost similar irrespective of treatment with EGF, AECS, and
p-BQ.
3.7. EGFR Exposed to AECS/p-BQ Cannot Bind c-Cbl and Is
Not Ubiquitinated. c-Cbl (120 kDa) is an E3 ubiquitin ligase
that plays a crucial role in downregulating the EGFR. On
EGFR activation, c-Cbl associates with phosphorylated Tyr-
1045 and ubiquitinates the receptor, marking it for clathrin-
mediated endocytosis and recognition by the lysosomal
machinery, which results in receptor degradation and signal
termination [37–40]. EGFR exposed to 100 ng/mL EGF, its
cognate ligand, is associated with c-Cbl and ubiquitinated
(Figure 9(a)). However, EGFR exposed to 2 μL/mL AECS
for 1 hr or 200 ng/mL p-BQ for 1 hr is not phosphorylated
on Tyr-1045, which renders it unable to associate with c-
Cbl and precludes it from being ubiquitinated (Figure 9(a)).
Therefore, under AECS/p-BQ exposure, c-Cbl loses its ability
to bind to EGFR and thereby lacks ubiquitination and
degradation, which leads to prolonged signaling even after
removal of the external stimuli AECS/p-BQ.
In order to study the fate of EGFR after incubation
with AECS/p-BQ followed by removal of these ligands, we
continued incubation of the cells for 2 hr more in serum-
free medium. The results (Figure 9(b)) indicate that EGFR
phosphorylation persists up to 2 hr after pretreatment with
2 μL/mL AECS or 200 ng/mL p-BQ followed by removal of
the ligands. This demonstrates that signals from activated
EGFR prolong apparently due to the inability of EGFR
degradation after AECS/p-BQ exposure. On the other hand,
when the cells were pretreated with 100 ng/mL EGF for 5 min
followed by removal of EGF, EGFR phosphorylation does
not prolong more than 15 min [29]. Here we show that
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Figure 9: EGFR exposed to AECS/p-BQ cannot bind c-Cbl and is not ubiquitinated. Serum-starved A549 cells were either nontreated
(NT) or exposed to 100 ng/mL EGF for 5 min (used as positive control), 2 μL/mL AECS or 200 ng/mL p-BQ for 1 hr. After treatment, cells
were immediately lysed, and the EGFR was immunoprecipitated (IP) from the cell lysates using anti-EGFR antibody. Immunoprecipitated
proteins were separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted (IB) with the indicated antibodies (a). Serum-
starved A549 cells were either nontreated (NT) or exposed to 100 ng/mL EGF for 5 min or 2 hr, 2 μL/mL AECS or 200 ng/mL p-BQ for 1 hr.
After treatment, cells were washed with PBS and further incubated in fresh serum-free medium for 2 hr at 37◦C before lysis. The EGFR
was immunoprecipitated (IP) from the cell lysates using anti-EGFR antibody. Immunoprecipitated proteins were separated by SDS-PAGE,
transferred to PVDF membrane, and immunoblotted (IB) with antiphosphotyrosine (PY20) antibody (b).
phosphorylation of EGFR by EGF is practically nil after 2 hr
(Figure 9(b)).
3.8. AECS/p-BQ Exposure Activates Hras + Kras Which Leads
to Downstream Survival and Proliferative Signaling ERK 1/2
and Akt. The Ras proteins are GDP/GTP-binding proteins
that act as intracellular signal transducers. The inactive forms
are GDP bound. They are activated by receptor tyrosine
kinases including EGFR. The most well studied members of
the ras gene family are Hras and Kras. These genes encode
immunologically related proteins with a molecular mass of
21 kDa and are homologs of rodent sarcoma virus genes
that have transforming abilities. While these wildtype cellular
proteins in humans play a vital role in normal tissue signal-
ing, including proliferation, differentiation, and senescence,
mutated or overexpressed genes are potent oncogenes that
play a major role in many human cancers including lung
cancer. Here, we show that exposure to 2 μL/mL AECS or
200 ng/mL p-BQ for 1 hr results in the overexpression of
Hras + Kras proteins (Figure 10, row 1).
In addition to Hras and Kras, two well-established
mediators of proliferation and cell survival, extracellular
signal-regulated kinase (ERK1/2), also called the mitogen-
activated protein kinase (MAPK), and Akt (also known
as protein kinase B), are known to be involved in cell
transformation when persistently activated [41–43]. It is
known that activation (phosphorylation) of the ERK1/2
pathway is involved in malignant transformation both in
vitro and in vivo. It is also reported that activation of ERK
1/2 is associated with nonsmall cell lung cancer (NSCLC),
80% of which is caused by cigarette smoking [44]. ERK
1/2 is activated by dual phosphorylation on both Thr202
and Tyr204 residues. Akt is a serine/threonine protein
kinase that plays a key role in multiple cellular processes,
including promotion of cell survival in several cell lines.
Activation of both ERK 1/2 and Akt in a variety of cells
is mediated mainly by growth factor receptors that require
EGFR phosphorylation [45]. Furthermore, lack of EGFR
turnover has been shown to mediate tumor promotion in
nonneoplastic rat liver epithelial cells [46]. Figure 10 (rows 2
and 4) shows that exposure to 2 μL/mL AECS or 200 ng/mL
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Figure 10: Exposure of A549 cells to AECS/p-BQ results in overex-
pression of Hras + Kras and activation of downstream proliferation
and survival signaling Akt and ERK 1/2. Serum-starved A549
cells were either nontreated (NT) or exposed to 2 μL/mL AECS
or 200 ng/mL p-BQ for 1 hr followed by incubation in serum
containing media for 6 hr. After 6 hr, cells were lysed, and cell lysates
were separated by SDS-PAGE, transferred to PVDF membrane, and
immunoblotted with antiphosphotyrosine (PY20), anti-HRAS +
KRAS, anti-phospho-Akt, anti-Akt, anti-phospho-ERK 1/2, and
anti-ERK 1/2 antibodies. β-actin was used as the loading control.
p-BQ for 1 hr results in the phosphorylation of downstream
ERK 1/2 and Akt signals that render them active. However,
the nontreated cells do not show any overexpression of
activated Hras + Kras, ERK 1/2, or Akt (Figure 10, rows 3
and 5).
3.9. AECS/p-BQ Exposure Results in Activation of c-Myc and
Overexpression of c-Fos. The c-Myc protein (49kDa) is a
transcription factor, which is encoded by the c-Myc gene on
human chromosome 8q24. The c-Myc oncoprotein is among
the most potent transforming agents in human cells. Elevated
levels of the c-Myc oncoprotein contribute to the initiation
and progression of most human tumors [47–49]. Increased
expression of c-Myc induces proliferation and inhibits
differentiation. c-Myc is commonly activated in a variety of
tumor cells and can either activate or repress the expression
of specific target genes associated with various biological
functions. Via this transcriptional regulatory activity, c-Myc
contributes to diverse aspects of cancer biology, including
cell cycle progression, angiogenesis, metastasis, cell adhesion,
cell growth, and genomic instability. Studies revealed a
functional association between phosphorylation of c-Myc at
Thr58/Ser62 by ERK 1/2 in cell proliferation and cell cycle
regulation [50].
c-Fos belongs to the Fos family of nuclear oncogenes.
The expression of c-Fos protein (62 kDa) is rapidly and tran-
siently induced by a variety of extracellular stimuli, including
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Figure 11: Exposure of A549 cells to AECS/p-BQ results in phos-
phorylation of c-Myc at Thr 58/Ser 62 and overexpression of c-Fos.
Serum-starved A549 cells were either nontreated (NT) or exposed
to 2 μL/mL AECS for 1 hr or 200 ng/mL p-BQ for 1 hr followed by
incubation in serum containing media for 6 hr. After 6 hr, cells were
lysed, and cell lysates were separated by SDS-PAGE, transferred to
PVDF membrane, and immunoblotted with anti-phospho-c-Myc
(phospho Thr58 + Ser62), anti-c-Myc, and anti-c-Fos antibodies.
β-actin was used as loading control.
growth factors. In addition to increased expression, phos-
phorylation of Fos proteins by ERK kinases in response
to external stimuli may further increase transcriptional
activity [51–54]. Deregulated expression of c-Fos can result
in neoplastic cellular transformation [51]. Figure 11 shows
that exposure of A549 cells to 2 μL/mL AECS or 200 ng/mL
p-BQ for 1 hr results in phosphorylation of c-Myc protein
at Thr58/Ser62 and overexpression of c-Fos. However, the
nontreated cells neither show any c-Myc phosphorylation
nor c-Fos expression.
4. Conclusion
Despite major advances in the treatment and management
of lung cancer, most patients with lung cancer eventually die
of this disease. Because conventional therapies have failed
to make a major impact on survival, newer approaches
are necessary in the battle against lung cancer [55]. It is
known that cigarette smoking is the strongest risk factor for
developing lung cancer. Eventually the best method to pre-
vent lung cancer is cessation of smoking, which has proven
difficult to achieve and unlikely to be accomplished. This
has motivated an intense interest in the chemoprevention
of this disease [56]. Cigarette smoke (CS) is a complex
mixture of about 4000 compounds [11, 12], and identifying
the risk factor in CS is essential for achieving this goal. We
have identified p-benzoquinone (p-BQ) as a risk factor that
is tentatively produced from p-benzosemiquinone [13–15]
of aqueous extract of CS (AECS). Lung cancer is believed
to arise after a series of progressive pathologic changes
(preneoplastic lesions) that are initiated by proliferation
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Figure 12: Model showing the molecular mechanisms of cigarette smoke-induced proliferation of human lung epithelial cells (A549) and
prevention by vitamin C as well as antibody to p-Benzoquinone.
[4]. We have shown that low concentration of AECS or
equivalent amount of p-BQ derived from AECS causes
excessive proliferation of human lung epithelial cells (A549)
that is mediated via aberrant phosphorylation of EGFR
resulting in persistent activation of EGFR. The prolonged
activation of EGFR is accompanied by activation of Ras, the
downstream survival, and proliferative signaling molecules
Akt and ERK1/2, as well as the transcription factors c-
Myc and c-Fos. Given that more than 80% of CS-induced
nonsmall cell lung carcinomas (NSCLCs) express EGFR
[2], inhibition of EGFR has become an important thera-
peutic target for the treatment of these tumors [28, 57,
58]. We have demonstrated that both anti-p-BQ antibody
and vitamin C prevent AECS/p-BQ-induced activation of
EGFR and proliferation of lung cells (Figure 12). Vitamin
C prevents AECS/p-BQ-induced proliferation apparently by
reducing and thereby inactivating p-BQ. We consider that
prevention of CS-induced proliferation of lung cells by
vitamin C and/or anti-p-BQ antibody may provide a novel
intervention for preventing initiation of CS-induced lung
cancer.
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